Table 2 Clinical evaluation of bone and joint tuberculosis patients from 2011 to 2015 in Shanghai
Clinical features | Native people | Migrant people | P value | ||
|---|---|---|---|---|---|
Duration of symptom onset to hospital | 5.63(1–72) | 8.57(1–36) | 0.007a | ||
Symptom | Pain | 50(92.59%) | 58(95.08%) | 0.705b | |
Night sweat | 15(27.78%) | 12(19.67%) | 0.306 | ||
Fever | 24(44.44%) | 25(40.98%) | 0.708 | ||
Cough | 7(12.96%) | 11(18.03%) | 0.455 | ||
Weight loss | 12(22.22%) | 10(16.39%) | 0.428 | ||
Paraplegia | 3(5.56%) | 9(14.75%) | 0.107 | ||
Limitations in activity | 23(42.59%) | 19(31.15%) | 0.203 | ||
Laboratory exam | Neutrophils (%) | 61.57(39.10–79.40) | 62.40(42.40–79.60) | 0.659 | |
ESR(mm/h) | 17.51(7.60–25.90) | 16.75(7.50–25.20) | 0.346 | ||
CRP(mg/l) | 13.57(9.22–20.22) | 13.13(8.45–21.23) | 0.358a | ||
Hemoglobin(g/l) | 111.98(86–143) | 112.89(80–139) | 0.733 | ||
T-SPOT | 24(64.86%) | 25(44.64%) | 0.056 | ||
Sputum culture | 31(73.81%) | 35(71.43%) | 0.800 | ||
Biopsies | 0 | 2 | / | ||
Radiological exam | Chest | negative | 24(44.44%) | 32(52.46%) | 0.442 |
moderate | 23(42.59%) | 19(31.15%) | |||
severe | 7(12.96%) | 10(16.39%) | |||
Joint | negative | 0 | 0 | 0.031 | |
moderate | 33(61.11%) | 25(40.98%) | |||
severe | 21(38.89%) | 36(59.02%) | |||
Infection site | Peripheral | Shoulder | 3(5.56%) | 4(6.56%) | 0.639 |
Elbow | 3(5.56%) | 3(4.92%) | |||
Wrist | 1(1.85%) | 1(1.64%) | |||
Hip | 4(7.41%) | 6(9.84%) | |||
Knee | 8(14.81%) | 3(4.92%) | |||
Ankle/foot | 3(5.56%) | 1(1.64%) | |||
Spine | Cervical | 7(12.96%) | 9(14.75%) | 0.649 | |
Thoracic | 8(14.81%) | 16(26.23%) | |||
Lumbar | 16(29.63%) | 16(26.23%) | |||
Paravertebral abscess | 1(1.85%) | 2(3.28%) | |||
Concomitant TB | Pulmonary | 22(40.74%) | 27(44.26%) | 0.888 | |
Lymph nodes | 2(3.70%) | 3(4.92%) | |||
Urinary tract and kidney | 2(3.70%) | 5(8.20%) | |||
Comorbidity | HT | 22(40.74%) | 10(16.39%) | 0.004 | |
DM | 21(38.89%) | 8(13.11%) | 0.001 | ||
RA | 6(11.11%) | 5(8.20%) | 0.596 | ||
HIV | 3(5.56%) | 3(4.92%) | 1.000 | ||
Syphilis | 3(5.56%) | 2(3.28%) | 0.664 | ||
Previous TB | 5(9.26%) | 7(11.48%) | 0.698 | ||
Cancer | 17(31.48%) | 9(14.75%) | 0.032 | ||
Drug resistant pattern | Isoniazid | 14(25.93%) | 18(29.51%) | 0.669c | |
Rifampin | 8(14.81%) | 11(18.03%) | 0.643c | ||
Ethambutol | 6(11.11%) | 8(13.11%) | 0.743c | ||
Streptomycin | 10(18.52%) | 11(18.03%) | 0.946c | ||
Multidrug resistance | 0 | 2(3.28%) | 0.497b | ||
Surgical intervention | 34(62.96%) | 32(52.46%) | 0.256 | ||
Infection | 5(9.26%) | 8(13.11%) | 0.515 | ||
Drug | 40(74.08%) | 46(75.41%) | 0.869 | ||
Mean time for anti-tuberculosis treatment | 8.96(6–12) d1 | 7.94(4–12) d2 | 0.003 | ||
Follow-up duration | 15.16(12–24)d1 | 13.63(12–23)d2 | 0.011a | ||